CCCC · C4 Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-10 | REYNO LEONARD |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
7,397 |
| 2026-07-10 | REYNO LEONARD |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on July 12, 2023. |
Common Stock
|
15,325 |
| 2026-07-01 | GROGAN DONNA ROY |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026. |
Common Stock
|
3,341 |
| 2026-07-01 | Anderson Kenneth Carl |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026. |
Common Stock
|
2,650 |
| 2026-06-24 | Bessen Laura |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-24 | Cooper Ronald Harold Wilfred |
Director, CEO & President |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-24 | Hughes Owen |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-24 | GROGAN DONNA ROY |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-24 | Koppikar Utpal |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-24 | Fawell Stephen |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-24 | Hoerter Steven L. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-24 | Anderson Kenneth Carl |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Stock Option (Right to Buy)
|
62,000 |
| 2026-06-01 | Anderson Kenneth Carl |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents the exercise of a stock option for cash. No shares were sold in connection with the exercise. The shares underlying this option are fully vested and exercisable. |
Stock Option (Right to Buy)
|
1,070 |
| 2026-06-01 | Anderson Kenneth Carl |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The reported transaction represents the exercise of a stock option for cash. No shares were sold in connection with the exercise. |
Common Stock
|
1,070 |
| 2026-04-01 | Anderson Kenneth Carl |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026. |
Common Stock
|
4,259 |
| 2026-04-01 | GROGAN DONNA ROY |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026. |
Common Stock
|
5,370 |
| 2026-02-15 | Hirsch Andrew |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
9,057 |
| 2026-02-15 | Hirsch Andrew |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. |
Common Stock
|
20,400 |
| 2026-02-14 | Mahaney Paige |
Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
2,446 |
| 2026-02-14 | Adams Kendra |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Common Stock
|
30,950 |
| 2026-02-14 | Hirsch Andrew |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
39,154 |
| 2026-02-14 | Schick Kelly |
Chief People Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
7,269 |
| 2026-02-14 | Boyle Scott N |
Chief Business Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Common Stock
|
7,269 |
| 2026-02-14 | Mossler Mark |
Chief Accounting Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on April 10, 2024 and February 18, 2025. |
Common Stock
|
9,420 |
| 2026-02-14 | Mahaney Paige |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of RSUs. The grant of RSUs was initially reported in Table I of the Forms 4 filed by the Reporting Person on February 18, 2025. |
Common Stock
|
7,050 |
| 2026-02-14 | Boyle Scott N |
Chief Business Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Common Stock
|
20,950 |
| 2026-02-14 | Schick Kelly |
Chief People Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Common Stock
|
20,950 |
| 2026-02-14 | Mossler Mark |
Chief Accounting Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
3,268 |
| 2026-02-14 | REYNO LEONARD |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
16,579 |
| 2026-02-14 | Hirsch Andrew |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. |
Common Stock
|
81,725 |
| 2026-02-14 | REYNO LEONARD |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 14, 2024 and February 18, 2025. |
Common Stock
|
30,950 |
| 2026-02-14 | Adams Kendra |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
15,381 |
| 2026-02-13 | Adams Kendra |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Common Stock
|
3,750 |
| 2026-02-13 | Boyle Scott N |
Chief Business Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
Common Stock
|
200,000 |
| 2026-02-13 | Mossler Mark |
Chief Accounting Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 28,490 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 28,490 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
Common Stock
|
56,980 |
| 2026-02-13 | Adams Kendra |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
Common Stock
|
240,000 |
| 2026-02-13 | Adams Kendra |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
1,863 |
| 2026-02-13 | Boyle Scott N |
Chief Business Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
1,735 |
| 2026-02-13 | Schick Kelly |
Chief People Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Common Stock
|
5,000 |
| 2026-02-13 | Hirsch Andrew |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
Common Stock
|
700,000 |
| 2026-02-13 | Schick Kelly |
Chief People Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
Common Stock
|
200,000 |
| 2026-02-13 | Mahaney Paige |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
Common Stock
|
240,000 |
| 2026-02-13 | REYNO LEONARD |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
Common Stock
|
240,000 |
| 2026-02-13 | Boyle Scott N |
Chief Business Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Common Stock
|
5,000 |
| 2026-02-13 | Schick Kelly |
Chief People Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
1,735 |
| 2026-01-16 | REYNO LEONARD |
Chief Medical Officer |
Sell↓
|
Common Stock
|
10,000 |
| 2026-01-02 | Anderson Kenneth Carl |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2026. |
Common Stock
|
5,958 |
| 2026-01-02 | GROGAN DONNA ROY |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2026. |
Common Stock
|
7,513 |
| 2025-10-28 | Mahaney Paige |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on October 28, 2024. |
Common Stock
|
19,200 |
| 2025-10-28 | Mahaney Paige |
Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Common Stock
|
5,644 |